A 70-year-old woman was diagnosed with a rare type of bladder cancer called primary mucinous adenocarcinoma. This cancer is hard to tell apart from other cancers that spread to the bladder. Doctors used a special set of lab tests, called immunohistochemical markers, to confirm the diagnosis. The markers included CK7 negative, CK20 positive, CDX-2 positive, and others.
The patient had surgery to remove the tumor and then a robot-assisted operation to remove the bladder. Six months later, she had no signs of cancer coming back or spreading. This is just one case, so we can't draw broad conclusions. But it shows how a targeted panel of markers can help diagnose this rare cancer.
Because there are no standard treatment guidelines for this cancer, doctors have to make decisions case by case. More research is needed to find the best treatments. This report adds to the small pool of knowledge about this disease.
Common questions
What is primary mucinous adenocarcinoma of the bladder?
It is a very rare type of bladder cancer that starts in the bladder itself. It looks like other cancers that spread to the bladder from elsewhere, so special tests are needed to tell them apart.
How was this cancer diagnosed?
Doctors used a panel of immunohistochemical markers, which are lab tests on the tumor tissue. The markers included CK7 negative, CK20 positive, CDX-2 positive, and others. This helped confirm it was primary bladder cancer.
What treatment did the patient receive?
The patient had a transurethral resection to remove the tumor, followed by robot-assisted radical cystectomy (removal of the bladder). At 6 months, there was no sign of cancer recurrence or spread.
Is this treatment standard for this cancer?
There are no standard treatment guidelines for this rare cancer. Treatment decisions are made case by case. This report highlights the need for more research to establish best practices.
